IceCure Medical Ltd. Announces Positive THERMAC Trial Results for ProSense® Cryoablation in Breast Cancer, Achieving High Patient Satisfaction and Complete Ablation Rates
Reuters
Sep 08
<a href="https://laohu8.com/S/ICCM">IceCure Medical Ltd.</a> Announces Positive THERMAC Trial Results for ProSense® Cryoablation in Breast Cancer, Achieving High Patient Satisfaction and Complete Ablation Rates
IceCure Medical Ltd. has announced two new publications from the independent THERMAC Trial featuring its ProSense® cryoablation system for early-stage breast cancer. The trial, conducted in the Netherlands, compared different thermal ablation methods, with ProSense® demonstrating the highest complete ablation rate without adverse events. The first article, published in the European Journal of Surgical Oncology, reported that 95% of patients were satisfied with the cosmetic outcomes of ProSense® cryoablation. The second article, published in Radiology, highlighted its superior performance compared to other thermal ablation techniques. These findings were previously presented at several medical conferences, including the European Conference on Interventional Oncology 2025 and the Society of Interventional Oncology 2025 Annual Meeting. The THERMAC Trial's phase II results suggest that cryoablation with ProSense® is the preferred technique for future comparisons with surgery in a phase III trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO67619) on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.